Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Algeta Appoints Dr Andreas Menrad as CSO

Published: Monday, August 19, 2013
Last Updated: Monday, August 19, 2013
Bookmark and Share
Dr Menrad will be responsible for developing and executing the Company’s research strategy.

Algeta ASA has announced the appointment of Dr Andreas Menrad as Chief Scientific Officer (CSO) and member of the executive management team.

In this newly created role, Dr Menrad will be responsible for developing and executing the Company’s research strategy, including its Targeted Thorium Conjugate (TTC) platform. He will lead a rapidly growing and highly experienced R&D team.

Dr Menrad will report directly to Andrew Kay, Algeta’s President & CEO, and takes up his position immediately.

Dr Menrad brings more than 20 years of experience in the pharmaceutical and biotech industry, with a strong background in oncology therapeutic development.

He joins Algeta from Ablynx NV, where he was CSO. Prior to this, Dr Menrad spent five years at Genzyme (Sanofi) in Cambridge (UK), where most recently he held the role of General Manager and Vice President of Antibody Therapeutics.

Before that, he spent 15 years at Schering AG in senior research roles focused on oncology and antibody engineering. He is an author on more than 30 patents and more than 25 peer-reviewed publications.

Dr Menrad received his PhD in Immunology from the University of Stuttgart and conducted post-doctoral research at the Wistar Institute Cancer Center (Philadelphia, PA, USA).

With the appointment of Dr Menrad, Dr Thomas Ramdahl, the Company’s Executive Vice President will become Algeta’s Chief Operating Officer (COO) with responsibilities for key aspects of the Company’s European operations, its global manufacturing assets as well as the intellectual property portfolio.

Andrew Kay, Algeta’s President & CEO, said: “Andreas brings a wealth of complementary skills and experience to Algeta from his successful career in therapeutic research and development. We are confident that, in this key strategic leadership role, he will guide the development and direction of our research team as we seek to create a pipeline of development candidates. I would also like to congratulate Thomas on his appointment as Algeta’s COO, a new position that reflects the Company’s commercial evolution and our global manufacturing capabilities.”

Andreas Menrad, Algeta’s Chief Scientific Officer, added: “Algeta has an exceptional opportunity to establish a leading position in the field of targeted cancer therapeutics, including via its unique thorium-227 alpha-pharmaceutical payload. I am excited to join the Company at a time of significant momentum and I look forward to working to further develop and advance Algeta’s world-class technologies and capabilities.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Long-Term Culturing of Adult Stem Cells
A new procedure developed by Harvard Stem Cell Institute researchers (HSCI) at Massachusetts General Hospital (MGH) may revolutionize the culturing of adult stem cells.
Solutions for Biotherapeutic Characterization
Innovation to speed the routine.
Plant-Based Vaccine Among Front Runners In Search For New Polio Jab
A researcher from Norwich is part of a consortium that has been awarded $1.5 million to develop safer polio vaccines, using a new technique developed at the John Innes Centre.
Harnessing Helpful Microbes
Seeking to further harness microbes’ many uses, the federal government has launched the National Microbiome Initiative (NMI) to “foster the integrated study of microbiomes across different ecosystems.”
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
Better Animal Model to Improve HIV Vaccine Development
Penn study identifies a new tool to produce better HIV vaccine designs.
First Large-Scale Proteogenomic Study of Breast Cancer
The study offers understanding of potential therapeutic targets.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!